

(43) International Publication Date
2 September 2010 (02.09.2010)(10) International Publication Number
WO 2010/099321 A1(51) International Patent Classification:
A61N 1/30 (2006.01)(21) International Application Number:
PCT/US2010/025416(22) International Filing Date:
25 February 2010 (25.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/155,880 26 February 2009 (26.02.2009) US(71) Applicants (for all designated States except US): **THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, NC 27599-4105 (US). **LIQUIDIA TECHNOLOGIES, INC.** [US/US]; 419 Davis Drive, Suite 100, Durham, NC 27713 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **DESIMONE, Joseph** [US/US]; 7315 Crescent Ridge, Chapel Hill, NC 27615 (US). **NAPIER, Mary** [US/US]; 106 Woods Walk Court, Carrboro, NC 27510 (US). **PILLAI, Jonathan** [IN/US]; 1002 Willow Drive, Apt. #105, Chapel Hill, NC 27514 (US). **BYRNE, James** [US/US]; 425 Hillsborough St, Apt. 9C, Chapel Hill, NC 27514 (US). **ROUSH, Lukas, Miller** [US/US]; 601 Highgrove Road, ChapelHill, NC 27516 (US). **YEH, Jen, Jen** [US/US]; 304 Lake Manor Road, Chapel Hill, NC 27516 (US). **PARROTT, Matt** [CA/US]; 222 Old Fayetteville Road, Apt. 301, Carrboro, NC 27510 (US).(74) Agents: **KIRK, Trent, A.** et al.; ALSTON & BIRD LLP, Bank Of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INTERVENTIONAL DRUG DELIVERY SYSTEM AND ASSOCIATED METHODS



(57) Abstract: A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.



Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

INTERVENTIONAL DRUG DELIVERY SYSTEM AND ASSOCIATED METHODS

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This disclosure was partially made with U.S. Government support under contract number CHE-9876674 awarded by the United States National Science Foundation and Technology Center. The U.S. Government may have certain rights in the disclosure.

5 BACKGROUND

Field of the Invention

Embodiments of the present invention relate to an interventional drug delivery system, and more particularly, to a system for facilitating delivery of various cargos, such as, for example, therapeutic agents, to target sites of internal body tissue *in vivo*, and
10 methods associated therewith, wherein the system implements an electric field to drive cargo through tissue as in iontophoretic approaches.

Description of Related Art

Many techniques exist for the delivery of drugs and therapeutic agents to the
15 body. Traditional delivery methods include, for example, oral administration, topical administration, intravenous administration, and intramuscular, intradermal, and subcutaneous injections. With the exception of topical administration which permits more localized delivery of therapeutic agents to particular area of the body, the aforementioned drug delivery methods generally result in systemic delivery of the therapeutic agent
20 throughout the body. Accordingly, these delivery methods are not optimal for localized targeting of drugs and therapeutic agents to specific internal body tissues.

As a result, other methods, such as endovascular medical devices, Natural Orifice Translumenal Endoscopic Surgery (NOTES)-based devices, and iontophoresis, have been developed to provide localized targeting of therapeutic agents to a particular internal
25 body tissue. Iontophoresis is a form of drug delivery that uses electrical current to enhance the movement of charged molecules across or through tissue. Iontophoresis is usually defined as a non-invasive method of propelling high concentrations of a charged substance, normally therapeutic or bioactive-agents, transdermally by repulsive

electromotive force using a small electrical charge applied to an iontophoretic chamber containing a similarly charged active agent and its vehicle. In some instances, one or two chambers are filled with a solution containing an active ingredient and its solvent, termed the vehicle. The positively charged chamber (anode) repels a positively charged
5 chemical, while the negatively charged chamber (cathode) repels a negatively charged chemical into the skin or other tissue. Unlike traditional transdermal administration methods that involve passive absorption of a therapeutic agent, iontophoresis relies on active transportation within an electric field. In the presence of an electric field, electromigration and electroosmosis are the dominant forces in mass transport. As an
10 example, iontophoresis has been used to treat the dilated vessel in percutaneous transluminal coronary angioplasty (PTCA), and thus limit or prevent restenosis. In PTCA, catheters are inserted into the cardiovascular system under local anesthesia and an expandable balloon portion is then inflated to compress the atherosclerosis and dilate the lumen of the artery.

15 The delivery of drugs or therapeutic agents by iontophoresis avoids first-pass drug metabolism, a significant disadvantage associated with oral administration of therapeutic agents. When a drug is taken orally and absorbed from the digestive tract into the blood stream, the blood containing the drug first passes through the liver before entering the vasculature where it will be delivered to the tissue to be treated. A large portion of an
20 orally ingested drug, however, may be metabolically inactivated before it has a chance to exert its pharmacological effect on the body. Furthermore it may be desirable to avoid systematic delivery all together in order to allow high doses locally while avoiding potential side effects elsewhere, wherein local delivery is desirable for localized conditions. Existing medical device technologies that enable localized placement of
25 therapeutics fail to provide the opportunity to embed / secure therapeutics in the tissue(s) of interest.

Accordingly, it would be desirable to provide an improved system and method for selectively and locally targeting delivery of various drugs and therapeutic agents to an internal body tissue, and fixing such cargos in the tissue(s) of interest *in vivo*.

SUMMARY

35 The above and other needs are met by aspects of the present invention which provide, in one instance, a delivery system, and in particular, a delivery system for local drug delivery to a target site of internal body tissue. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body

tissue. A counter electrode is in electrical communication with the source electrode. The counter electrode is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. An electrode deployment device may be used and is configured to insert at least one of the source electrode and the counter electrode proximate to the target site of internal body tissue *in vivo*. A reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field formed between the source electrode and the counter electrode. In some aspects, the drug reservoir is capable of being remotely filled with the cargo.

Another aspect provides a method for delivering a cargo to a target site of internal body tissue. Such a method comprises disposing a source electrode proximate to a target site of internal body tissue *in vivo* using an electrode deployment device, and disposing a counter electrode in electrical communication with the source electrode, wherein the counter electrode is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. The method further comprises disposing a reservoir such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field formed between the source electrode and the counter electrode. In some aspects, the drug reservoir is capable of being remotely filled with the cargo. The method further comprises applying a voltage potential across the source and counter electrodes to form an electric field, thereby delivering at least a portion of the cargo to the target site.

Yet another aspect provides a method of treating a target site of internal body tissue. Such a method comprises delivering a therapeutic agent to a body cavity of a patient for storage thereof. The method further comprises positioning a first electrode proximate to a target site of body tissue, and positioning a second electrode such that the second electrode is in electrical communication with the first electrode. The method further comprises applying a voltage potential across the first and second electrodes to drive the therapeutic agent from the body cavity to the target site.

As such, embodiments of the present invention are provided to enable highly targeted and efficient delivery of various cargos to predetermined target sites. In this regard, aspects of the present invention provide significant advantages as otherwise detailed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to assist the understanding of embodiments of the invention, reference will now be made to the appended drawings, which are not necessarily drawn to scale. The drawing is exemplary only, and should not be construed as limiting the invention.

5 **FIGS. 1A-1G** are schematic drawings of various embodiments of a delivery system having a source electrode and counter electrode configured to cooperate to form an electric field for delivering a cargo, according to one embodiment of the present disclosure;

10 **FIG. 2** is a partial view of a delivery system having a source electrode with an array of probes, according to an alternative embodiment of the present disclosure;

FIG. 3 is a partial view of a delivery system having a source electrode with an array of probes, according to yet another embodiment of the present disclosure;

15 **FIG. 4** is a partial view of a delivery system according to one embodiment of the present disclosure, illustrating a source electrode having a plurality of insulating members engaged therewith;

20 **FIG. 5** is a partial view of a delivery system disposed within a tissue lumen, the delivery system having a plurality of independently controlled source electrodes and a plurality of insulating members configured to provide controlled delivery zones for specific targeting of target sites of the tissue lumen, according to one embodiment of the present disclosure;

25 **FIG. 6** is a partial view of a delivery system employing a catheter device for positioning of a source electrode, wherein the delivery system includes a plurality of independently controlled source electrodes and a plurality of insulating members configured to provide controlled delivery zones for specific targeting of target sites, according to one embodiment of the present disclosure;

FIG. 7 is a partial view of a delivery system having a source electrode encapsulated by a polymer matrix reservoir having a cargo contained therein, according to one embodiment of the present disclosure;

30 **FIGS. 8A and 8B** are partial views of a delivery system having a source electrode with at least one insulating member engaged therewith, the source electrode and at least one insulating member being encapsulated by a polymer matrix reservoir having a cargo contained therein;

35 **FIG. 9** is a partial view of a delivery system having a plurality of independently controlled source electrodes and a plurality of insulating members arranged to provide controlled delivery zones, wherein the source electrodes and the insulating members are encapsulated in a polymer matrix, according to one embodiment of the present disclosure;

FIG. 10 is a partial view of a delivery system having a source electrode serially disposed between a pair of expandable members configured to occlude a target site, wherein the expandable members are in a relaxed state, according to one embodiment of the present disclosure;

5 **FIG. 11** is a partial view of the delivery system of **FIG. 10**, illustrating the expandable members in an expanded state so as to occlude the target site such that delivery of a cargo is limited thereto;

10 **FIG. 12** is a partial view of a delivery system having a source electrode comprising a hollow tube needle member configured to deliver a cargo to a target site of internal body tissue, according to one embodiment of the present disclosure;

FIGS. 13A and 13B are partial views of a delivery system having a counter electrode positioned at various orientations with respect to the source electrode so as to target delivery of a cargo to a target site to predetermined *in vivo* locations;

15 **FIG. 14** is a partial view of a delivery system having a coolant device extending about a counter electrode to provide cooling thereto, the coolant device having a membrane portion disposed about the counter electrode, according to one embodiment of the present disclosure;

20 **FIG. 15** is a partial view of a delivery system having a coolant device extending about a counter electrode to provide cooling thereto, wherein the counter electrode is disposed between an insulating member and a membrane portion of the coolant device, according to one embodiment of the present disclosure;

25 **FIG. 16** is a partial view of a delivery system having a coolant device extending about a counter electrode to provide cooling thereto, the coolant device having an aperture disposed at a distal end thereof for permitting a coolant substance to exit therefrom;

FIGS. 17A and 17B are images illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIGS. 18A and 18B are images illustrating an experimental implementation of a delivery system in accordance with another aspect of the present disclosure;

30 **FIGS. 19A-19C** are images illustrating an experimental implementation of a delivery system in accordance with yet another aspect of the present disclosure;

FIGS. 20A and 20B are images illustrating an experimental implementation of a delivery system in accordance with still another aspect of the present disclosure;

35 **FIG. 21** is an image illustrating an experimental implementation of a delivery system in accordance with another aspect of the present disclosure;

FIG. 22 is an image illustrating an experimental implementation of a delivery system in accordance with still yet another aspect of the present disclosure;

FIGS. 23A and 23B are images illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIGS. 24A and 24B are images illustrating an experimental implementation of a delivery system in accordance with yet another aspect of the present disclosure;

5 **FIG. 25** is an image illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIGS. 26A and 26B are images illustrating an experimental implementation of a delivery system in accordance with yet another aspect of the present disclosure;

10 **FIG. 27** is an image illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIGS. 28A and 28B are images illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIG. 29 is an image illustrating an experimental implementation of a delivery system in accordance with another aspect of the present disclosure;

15 **FIGS. 30A-30C** are images illustrating an experimental implementation of a delivery system in accordance with another aspect of the present disclosure;

FIGS. 31A and 31B are images illustrating an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

20 **FIG. 32A** illustrates an experimental implementation of a delivery system in accordance with one aspect of the present disclosure;

FIG. 32B shows results of an evaluation of the experimental implementation of **FIG. 32A** according to one aspect of the present disclosure;

FIGS. 33A-33D depict various perspective views of a delivery system in accordance with another aspect of the present disclosure;

25 **FIG. 34** shows experimental results of an evaluation of an experimental implementation according to one aspect of the present disclosure;

FIG. 35 illustrates experimental results of an evaluation of an experimental implementation according to one aspect of the present disclosure;

30 **FIG. 36** is an image illustrating an experimental implementation of a delivery system in accordance with an additional aspect of the present disclosure; and

FIG. 37 depicts exemplary dimensions of an experimental implementation of a delivery system in accordance with one aspect of the present disclosure.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

35 Embodiments of the present invention now will be described more fully hereinafter with reference to the accompanying drawings. The invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth

herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout.

Embodiments of the present invention are directed to systems and methods for delivering treatment or therapeutic agents (otherwise referred to herein as "cargo") to specific locations, including intracellular locations in a safe and effective manner. Such systems may deliver the agents to a diseased site in effective amounts without endangering normal tissues or cells and thus reduce or prevent the occurrence of undesirable side effects. Further, such systems may electrically enhance the local delivery of treatment agents into the wall tissues or cells of the living body. These systems are designed to target certain tissue and cell locations and deliver the treatment agents directly to those locations, while minimizing any effects on non-targeted tissues and cells. In particular, embodiments of the present invention relate to systems which provide an electrical driving force that can increase the rate of migration of drugs and other therapeutic agents out of a reservoir into body tissues and cells using iontophoresis and other approaches.

More particularly, embodiments of the present invention rely on the transport of charged and uncharged species under the influence of a localized electric field generated at the site of interest. The overall transport of charged and uncharged species is based upon three characteristic driving forces, which includes passive diffusion, electroosmosis, and electromigration. Passive diffusion involves the movement of a chemical species from a region of high concentration to an area of low concentration. Electroosmosis is the movement of a solute species via a solvent flow accompanied by the movement of an extraneous charged species. Electroosmosis encompasses the solvent flow referred to as hydrokinesis. Electromigration is the movement of a charged species through an applied electric field to an electrode of opposite polarity. Transport of a neutrally charged species is driven by passive diffusion and electroosmosis only, whereas all transport modalities, passive diffusion, electroosmosis, and electromigration contribute to the flux of a charged species.

In this regard, embodiments of the present invention may provide an interventional drug delivery system and methods for localized delivery of therapeutic agents to internal locations in the human body using a controlled electrical field. The systems may be constructed to deliver the agents specifically to the site of interest, improving penetration of the agent while limiting effect upon non-targeted tissue. Embodiments of the present invention may be fashioned to deliver the agents via intravascular, intraperitoneal, minimally invasive surgery, and natural orifice transluminal endoscopic surgery (NOTES) modalities. The action of the electric field may be controlled through a programmable power supply or a function generator. By using various electrode designs and placement

configurations, highly localized and focused delivery of cargo to the tissue of interest may be achieved. The overall controlled release characteristics of the delivery system may be dependent upon the charge, size, conductivity, concentration, and pK_a of the chemical species and nanoparticles, pH of the surrounding environment, resistance of the site of interest, current and voltage applied, electrode design and amount of extraneous ions at site of interest.

Embodiments of the present invention may be implemented in the delivery of therapeutic agents for such diverse areas as oncology, pulmonary, gastrointestinal (GI), and neurology applications. Embodiments of the present invention find application in the field of interventional oncology for the treatment of various cancers, which may include, for example, pancreatic cancers, lung cancer, esophageal cancers, bladder cancers, colorectal cancers, liver cancers, hepatic metastases, bile duct cancers, renal cancers, cervical cancers, prostate cancers, ovarian cancer, thyroid cancers, uterine cancers, and leukemia. In particular, accessing bone marrow tissue may be advantageous. Other applications may cover pulmonary diseases, neurological disorders as well as cardiovascular applications.

In some instances, embodiments of the present invention may employ an approach using iontophoresis. As used herein, the term "iontophoresis" means the migration of ionizable molecules through a medium driven by an applied low level electrical potential. This electrically mediated movement of molecules into tissues is superimposed upon concentration gradient dependent diffusion processes. If the medium or tissue through which the molecules travel also carries a charge, some electro-osmotic flow occurs. However, generally, the rate of migration of molecules with a net negative charge towards the positive electrode and vice versa is determined by the net charge on the moving molecules and the applied electrical potential. The driving force may also be considered as electrostatic repulsion. Iontophoresis usually requires relatively low constant DC current in the range of from about 2-5 mA. The applied potential for iontophoresis will depend upon number of factors, such as the electrode configuration and position on the tissue and the nature and charge characteristics of the molecules to be delivered.

The present invention relates to the delivery of cargo including, but not limited to, therapeutic agents such as drug molecules, proteins, peptides, antibodies, antibody scaffolds or fragments of antibodies, nucleotides, contrast agents and dyes (including radiolabels, fluorophores and chelated magnetic species), liposomes, micelles, nanoparticles, multi-molecular aggregates (such as, for example, albumin/paclitaxel or Abraxane™) and combinations thereof, with or without cargo and/or targeting capabilities. Small molecules may include chemotherapeutic agents such as alkylating agents, anti-

metabolites, plant alkaloids and terpenoids, vinca alkaloids, podophyllotoxin, taxanes, topoisomerase inhibitors, and antitumor antibiotics, as well as analgesics and local anesthetics. Embodiments of the present invention also covers the delivery of pro-drugs, small molecules and nanoparticles, in some instances having neutral charge before
5 delivery, that may be subsequently charged or triggered to release cargo under physiological conditions.

Furthermore, the cargo may include small ionic molecules, nucleic acids, proteins, therapeutic agents, diagnostic agents, and imaging agents as well as organic nanoparticles which may encapsulate a wide range of therapeutic, diagnostic, and
10 imaging agents. The cargo may be configured to traffic preferentially based on size, shape, charge and surface functionality; and/or controllably release a therapeutic. Such cargos may include but are not limited to small molecule pharmaceuticals, therapeutic and diagnostic proteins, antibodies, DNA and RNA sequences, imaging agents, and other active pharmaceutical ingredients. Further, such cargo may include active agents which
15 may include, without limitation, analgesics, anti-inflammatory agents (including NSAIDs), anticancer agents, antimetabolites, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives
20 (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, therapeutic proteins, enzymes, lipid regulating agents, muscle relaxants,
25 parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, and antiviral agents. In addition, the cargo may include a polynucleotide. The polynucleotide may be provided as an antisense agent or interfering RNA molecule such as an RNAi or siRNA
30 molecule to disrupt or inhibit expression of an encoded protein.

Other cargo may include, without limitation, MR imaging agents, contrast agents, gadolinium chelates, gadolinium-based contrast agents, radiosensitizers, such as, for example, 1,2,4-benzotriazin-3-amine 1,4-dioxide (SR 4889) and 1,2,4-benzotriazine-7-amine 1,4-dioxide (WIN 59075); platinum coordination complexes such as cisplatin and
35 carboplatin; anthracenediones, such as mitoxantrone; substituted ureas, such as hydroxyurea; and adrenocortical suppressants, such as mitotane and aminoglutethimide.

In other embodiments, the cargo may comprise Particle Replication In Non-wetting Templates (PRINT) nanoparticles (sometimes referred to as devices) such as disclosed, for example, in PCT WO 2005/101466 to DeSimone et al.; PCT WO 2007/024323 to DeSimone et al.; WO 2007/030698 to DeSimone et al.; and WO 2007/094829 to DeSimone et al., each of which is incorporated herein by reference.

PRINT is a technology which produces monodisperse, shape specific particles which can encapsulate a wide variety of cargos including small molecules, biologics, nucleic acids, proteins, imaging agents. Cationically charged PRINT nanoparticles smaller than 1 micron are readily taken up by cells over a relatively short time frame, but penetration of the particles throughout the tissue is a longer process. For the delivery of PRINT nanoparticles throughout the tissue to be effective, the penetration needs to occur within a reasonable operational time frame. As such, the delivery system may be used to achieve such penetration by employing iontophoresis, in which charged PRINT nanoparticles are driven into body tissue using repulsive electromotive forces. The PRINT particles may or may not contain a therapeutic. In some instances, the particle may be comprised of PLGA. In addition, the PRINT nanoparticles may be engineered to achieve a certain mission, and design-in handles that permit remote control for externally turning the cargo "on" or switching it "off". As such, the cargo may be manipulated using ultrasound, low-dose radiation, magnetics, light and other suitable mechanisms. The particles may be coated with gold such as, for example, gold nano-shells for thermal ablation therapy.

FIGS. 1-15 illustrate various embodiments and aspects of a delivery system **100** in accordance with the present invention. In general, the delivery system is provided for delivering a cargo to, or through, a localized area of a passageway or other internal body tissue in order to treat the localized area of the passageway or tissue with minimal, if any, undesirable effect on other body tissue. Such a system may be implemented intraluminally, through natural orifices, or by minimally invasive surgery such that the system may be used *in vivo*. The delivery system **100** may generally include a source electrode, a counter electrode, a reservoir for carrying a cargo (e.g., a therapeutic agent), and an electrode deployment device.

As described previously, the delivery apparatus **100** which may deliver cargo iontophoretically to target sites for localized treatment. In general, iontophoresis technology uses an electrical potential or current across a target site (e.g., a semipermeable barrier) to drive ionic fixatives or drugs (or drive nonionic fixatives or drugs) in an ionic solution. Iontophoresis facilitates both transport of the fixative or drug across the target site and enhances tissue penetration. In the application of iontophoresis, two electrodes, a source electrode and a counter electrode (in some

instances, the electrodes may be positioned on opposing sides of the target site, though such a configuration or arrangement is not required), are utilized to develop the required potential or current flow. The positioning of the electrodes may be accomplished using an electrode deployment device **150**. The electrode deployment device **150** may be capable of positioning the source electrode, the counter electrode, and the reservoir such that the therapeutic agents may be delivered through intravascular, intraperitoneal, and natural orifice transluminal endoscopic surgery (NOTES) modalities. Some embodiments of the present invention may employ the technique of reverse iontophoresis, wherein a small molecule or other substance may be extracted from the surrounding medium. In this manner, toxic substances or excess cargo materials may be removed from locations *in vivo*.

In some instances, the electrode deployment device **150** may comprise a catheter device to be deployed *in vivo* using the intravascular route. In other embodiments, the electrode deployment device **150** may comprise an endoscopic device for deployment via natural orifices in the body. In other instances, the electrode deployment device **150** may comprise a laparoscopic device for minimally invasive surgical intervention. In other embodiments, the electrode deployment device **150** may be surgically implanted in a suitable location *in vivo*, such as, for example, the peritoneal cavity. In yet other instances, the electrode deployment device **150** may implement combinations of two or more of the embodiments listed above. According to some embodiments, the electrode deployment device **150** may locate the source electrode, counter electrode, and/or reservoir at the target site of interest through use of an imaging system.

FIGS. **1-11** illustrate various embodiments of a source electrode **200** implemented by the delivery system **100**. The repulsive force for driving the charged cargo through the target site tissue is generated by placing the source electrode **200** at or proximate to the target site of interest. The delivery system **100** may include one or more source electrodes **200**. By optimizing the placement and geometric profile of the source electrode(s) **200**, considerable control may be achieved over the penetration depth, direction and overall area of delivery of the cargo to the target site. The source electrode(s) **200** may be configured as a single probe or an array of probes comprised, for example, of thin wires, foil, mesh, pellets, disks, stents, clamps, prongs, clips, needles, hollow tubes or combinations thereof. For example, as shown in FIG. **1**, the source electrode **200** may include a mesh arrangement **225** (see also FIGS. **1B**, **1C**, and **18B**) opposably positioned with respect to a counter electrode **500**. In accordance with such an embodiment, in some instances, the counter electrode **500** may be positioned, for example, on an exterior surface of the pancreas/organ of interest. The source electrode

200 having the mesh arrangement **225** may also be placed on the exterior surface to cover a specific target tissue such as, for example, a tumor, as shown in FIG. **1B**.

In another embodiment, the mesh arrangement **225** source electrode **200** may be configured to encase part or a portion of the target tissue (e.g., a conical mesh encasing the tail of the pancreas, as shown in FIG. **1C**). In other instances, the source electrode **200** may be configured or arranged as foil or patch electrodes **235**, as shown in FIG. **1D**, wherein the drug reservoir **300** is coupled to the source electrode **200**. The patch source electrode **235** may be configured as clamps or prongs situated at the end of the electrode deployment device **150**, such as, for example, an endoscopic or laproscopic device, as shown in FIG. **2**, wherein an intermediary prong **208** may include the patch source electrode **235**. In this regard, the configuration may be modified to be internally deployed by the electrode deployment device **150**, wherein the mesh arrangement **225** may be replaced by a stent device **245** (acting as the source electrode **200**), as shown in FIG. **1E**, that is positioned within the pancreatic duct **20**, while the counter electrode **500** may be positioned within an alternate branch of the same duct or, alternatively, the bile duct **25** for example, as shown in FIG. **1F**. In some instances, the source electrode may include a reservoir **300** coupled or otherwise attached thereto for holding the cargo to be delivered to the target site. In this manner, the reservoir **300** and/or the tissue of interest may be at least partially disposed between the source electrode **200** and the counter electrode **500**. The source electrode(s) **200** may be fabricated from various materials including, but not restricted to, conducting metals, such as silver, silver chloride, platinum, aluminum, or conducting polymers such as polypyrrole, polyaniline, or polyacetylene. In some instances, both the source electrode **200** and the counter electrode **500** may be patch source electrodes **235**, which may be positioned in a side-by-side or otherwise proximally positioned on an organ, tissue, or other target site, as shown in FIG. **1G**. That is, the cargo of the reservoir **300** may penetrate the target site to reach, for example, a tumor when the voltage potential is applied between the source electrode **200** and the counter electrode **500**. Of course, the patch source electrodes **235** may be on opposite sides of the organ, tissue, or target site, or may be otherwise appropriately configured to deliver the cargo to the target site.

According to some embodiments, the source electrode **200** may include an array of multi-functional probes, combining imaging and drug delivery functionalities, as illustrated in FIGS. **2** and **3**. In this regard, the use of paramagnetic or radio-opaque materials in the probe body may be used for imaging purposes. In other instances, catheter devices may be capable of simultaneous delivery of imaging agents. According to other embodiments, the incorporation of a light source and camera may be incorporated into the probe for endoscopic devices. Various combinations of such

imaging and delivery probes may be implemented by the delivery system **100**. For example, as illustrated in FIG. **2**, the intermediary prong **208** may include the electrode element **204**, while the outer prongs **210**, **212** include imaging devices and/or agents capable of assisting with positioning of the source electrode **200**. With reference to FIG.

5 **3**, the electrode element **204** may be radially surrounded by imaging devices **210** or agents, other source electrodes **200** or other probe members, which may be configured as dependent on the location of the target site within a patient's body.

In some instances, the source electrode **200** may have one or more insulating layers or members **250** attached, connected, or otherwise engaged therewith. The
10 insulating members **250** are provided to confer directionality to the transport profile of the cargo **60** with respect to the target site, as shown in FIG. **4**, illustrating the source electrode **200** disposed within a tissue lumen **50**. That is, the flux of the cargo will be attenuated corresponding to the insulated areas of the source electrode **200**. In this regard, a partially insulated source electrode **200** may be for control over targeted
15 delivery to specific *in vivo* locations. That is, by insulating a portion of the source electrode surface, control over delivery to the tissue or organ systems may be accomplished in a well defined manner. In this regard, the extent of transport from the sections of the target site exposed to the unshielded sections of the source electrode **200** may be greater than that of the transport from the shielded or insulated region of the
20 source electrode **200**.

According to some aspects of the present invention, a plurality of source electrodes **200** may be provided, wherein each source electrode **200** is independently controlled with respect to the other source electrodes **200**. In this manner, the delivery system **100** may be manipulated to target various sites for delivery of the cargo **60**, as
25 shown in FIG. **5**, illustrating the source electrodes **200** disposed within a tissue lumen **50**. That is, by allowing independent control over parameters for iontophoretic delivery such as current, voltage and time, variable delivery zones may be created at distinct sites within the same tissue lumen. In addition, the source electrodes **200** may terminate at various lengths to further provide control over deliver of the cargo to the target site(s).
30 Furthermore, in some instances, the plurality of source electrodes **200** may have the insulating members **250** disposed therebetween and thereabout to also specifically designate delivery regions **260** for delivery of the cargo **60** to the target site(s). According to an alternative embodiment, the source electrodes may be disposed within the electrode deployment device **150**, such as, for example, a catheter device **350**, as
35 illustrated in FIG. **6**. The catheter device **350** may be comprised of a perforated polymer sheath **352**. That is, the catheter device **350** may have a plurality of perforations **354** defined thereby such that the cargo **60** may exit the catheter device **350**. In one

particular embodiment, the source electrodes **200** terminate at different lengths and may be independently powered such that the probes are capable of being variably controlled. The source electrodes **200** may include the insulating members **250** disposed about and between the source electrodes **200** so as to form cargo delivery zones substantially
5 aligned with the perforations **354** of the catheter device **350**. In this regard, the cargo **60** may be fed through the catheter device **350** proximate to the target site at the terminal portion of the catheter device **350**, where the cargo **60** may be drawn therefrom due to the electrical field applied across the source electrode **200** and the counter electrode.

Referring to FIG. **7**, in some instances, the source electrode **200** (and/or the
10 counter electrode) may be encapsulated in a gelatinous solid, such as, for example, a soft polymer matrix **280**, that prevents injury from the insertion and extraction of the source electrode **200** (and/or the counter electrode). The polymer matrix **280** may also serve as a cargo reservoir **300** from where the therapeutic agent(s) may be mobilized. That is, the cargo **60** may be incorporated in the polymer matrix **280** such that, upon actuation of the
15 electric field, the cargo **60** may diffuse out of the polymer matrix **280** and be delivered to the target site. FIGS. **8A** and **8B** illustrate the source electrode **200** having one or more insulating members **250** disposed thereabout such that both the source electrode **200** and the insulating members **250** are encapsulated in the polymer matrix **280**. FIG. **8A** shows a single insulating member **250** disposed longitudinally along the source electrode
20 **200** such that the cargo **60** may be directed toward the target site. FIG. **8B** shows a plurality of insulating members **250** engaged with the source electrode **200** such that various cargo delivery regions or zones are defined for delivering the cargo **60** to specific areas of the target site. In this regard, there may be a region or regions **290** of depleted cargo within the polymer matrix **280** and a normal region or regions **295** at some duration
25 after actuation of the electric field to drive the cargo **60** toward the target site.

FIG. **9** illustrates an embodiment of the delivery system **100** similar to that of FIG. **5**, wherein a plurality of independently controlled source electrodes **200** may be provided such that various target sites and/or regions may be targeted for delivery. As described previously, the length at which the source electrodes **200** terminate may alter and the
30 insulating members **250** may be provided to further control delivery of the cargo **60**. In some instances, as shown in FIG. **9**, the source electrodes **200** and insulating members **250** may be encapsulated in a gelatinous solid such as, for example, the polymer matrix **280** carrying the cargo **60** therewith. In this manner, there may be a region **290** of depleted cargo within the polymer matrix **280** and a normal region **295** at some duration
35 after actuation of the electric field to drive the cargo **60** toward the target site.

In one embodiment, as illustrated in FIGS. **10** and **11**, a catheter device, such as, for example, a balloon catheter **400** having a pair of expandable members **402** may be

used to deliver the cargo **60** to the target site. The source electrode **200** may be serially disposed between the pair of expandable members **402**, which are configured to occlude a target site. In this regard, the expandable members **402** may be used to enclose or occlude an intraluminal area before and/or after the source electrode **200**, to limit the delivery of the cargo (e.g., therapeutic agent) to the area of interest. That is, the expandable members **402** may be in a relaxed state (FIG. **10**) during positioning of the catheter and/or source electrode **200** proximate to the target site. Thereafter, the expandable members **402** may be inflated to an expanded state (FIG. **11**) so as to contact a duct or other passageway **410** to enclose the target site such that the cargo delivery is isolated to the target site, thereby limiting exposure of healthy tissue to the cargo materials. In one embodiment, the delivery system **100** may include inflatable members **402**, as schematically shown in FIGS. **10** and **11**, which illustrate the distal end of the catheter device **400** with the expandable member **402** in its relaxed and inflated/expanded states, respectively. The catheter device **400** may include a guide wire for positioning the catheter device **400** near the target site. The term catheter as used in the present application is intended to broadly include any medical device designed for insertion into a body passageway to permit injection or withdrawal of fluids, to keep a passage open or for any other purpose. In other instances, an area to be treated may be occluded by blocking or damming an area using a balloon or a polymer cap or fibers (not shown).

With reference to FIG. **12**, in some embodiments of the present invention, placement of the cargo, such as the PRINT nanoparticles, may be achieved by using a hollow tube needle member **500** having an iontophoretic tip to facilitate distribution of the particles into the surrounding target site (tissue). In such embodiments, the needle tip may represent the source electrode **200**, while the counter electrode is positioned internally or external to the body so as to create a voltage potential when a power supply is energized, as described previously with respect to iontophoretic techniques. Such a technique may be used for disease states including cancer (brain, prostate, colon, others), inflammation, damaged tissue 'rescue' situations (e.g. cardio/neuro/peripheral vascular), ocular diseases, rhinitis, and other applications. Furthermore, the hollow tube portion of the needle member **500** may serve as a reservoir for the cargo, wherein the needle member **500** may be connected to a port member (not shown) located externally such that the reservoir may be filled and/or refilled externally.

Referring to FIGS. **13A**, **13B**, **14**, **15**, and **16**, one or more counter electrodes **500** may be provided with the delivery system **100**, wherein the counter electrode **500** consists of a probe of opposite polarity to that of the source electrode **200** that completes the electrical circuit of the system. That is, in using embodiments of the present invention

for iontophoretically enhanced drug delivery, a separate electrode of opposite polarity to the source electrode **200** is used in order to generate the potential gradient across the artery or other body tissue. In some instances, the counter electrode **500** may be positioned internally or otherwise external to the body such as on the patient's body
5 (usually the skin) and may be attached using any known means, such as ECG conductive jelly. That is, placement of the source electrode **200** and the counter electrode **500** may be altered to fit the tissue location and disease state to be treated. For example, the source electrode **200** and the counter electrode **500** may be placed internally, externally or one internal and one external as long as appropriate electrical connection can be
10 made. Internally placed electrodes can be proximal or distal in relation to each other and the tissue.

In some instances, as shown in FIGS. **13A** and **13B**, the counter electrode **500** may be designed to maximize movement of the cargo (e.g., the therapeutic agent) towards itself and away from the source electrode **200** so as to promote distinct and
15 varied delivery zones **550**. That is, the position of the counter electrode **500** may be manipulated to exert control over targeted delivery to specific *in vivo* locations. For example, as shown in the configuration of FIG. **13A**, the counter electrode **500** may be positioned substantially perpendicularly with respect to the source electrode **200**, whereas, as shown in the configuration of FIG. **13B**, the counter electrode **500** may be
20 concentrically positioned about the source electrode **200**. Such configurations of the counter electrode **500** may lead to highly directional transport or broader transport bands, as dependent on the configuration and orientation with respect to the source electrode **200**.

In some instances, the counter electrode **500** can have an ion selective
25 membrane portion **502** for the movement of ions to and from the counter electrode **500**. In some instances, the counter electrode **500** may have a coolant device **510** for use therewith to maintain the temperature of the counter electrode **500** and to minimize the potential for tissue burns, as illustrated in FIGS. **14-16**. The coolant device **510** may be configured to allow a coolant substance **512** to flow at least partially about the counter
30 electrode **500**. In this regard, the membrane portion **502** may be positioned to prevent ions that may be part of the coolant substance **512** from interfering with the cargo, drug, or material to be deposited. In some embodiments, the coolant device **510** may include a perforated tubular structure **514** defining an aperture **516** to allow for release of the coolant around the counter electrode **500**, as shown in FIG. **16**. The coolant substance
35 **512** may be, for example, water, an electrolyte solution, or gel-like substance that has a high heat capacitance to maintain cooler temperatures. In addition to performing a cooling function, the coolant substance **512** may allow for a continuous flow of

electrolytes for maximum ion transfer into the tissue, and maintain pH levels around the counter electrode **500**. A gelatinous membrane around the counter electrode **500** may also be utilized, to minimize pH changes occurring at the conducting surface and tissue interface. In one particular embodiment, the counter electrode **500** may be disposed
5 between the insulator member **250** and the membrane portion **502** so as to improve delivery control of the cargo to the target site.

Embodiments of the present invention further comprise a reservoir (see, for example, FIGS. **1**, **6-9**, and **12**) configured to store or otherwise carry the cargo such that the cargo may be at least partially disposed between the source electrode **200** and the
10 counter electrode **500**. In this manner, the cargo may interact with the electric field formed between the source electrode **200** and the counter electrode **500** so as to be delivered to the target site. The reservoir can be maintained as a solution, dispersion, emulsion or gelatinous solid, as previously describe with respect to FIGS. **7-9**. The reservoir entraps the cargo (e.g., the therapeutic agent) until the application of a physical,
15 chemical, or electrical stimulus. In one embodiment, the cargo reservoir may be located remotely from the source electrode **200** and may be connected to the source electrode **200** via a hollow conduit. In another embodiment, the reservoir and the source electrode **200** may be designed to be a single assembly. In any instance, it may be possible to refill the reservoir, either remotely or after every use. Large, medium, and small reservoirs
20 may be provided to allow for directionality and concentration of the cargo (e.g., the therapeutic agent) issued to the tissue of interest.

In one particular embodiment of the present invention, the intraperitoneal cavity may serve as the drug reservoir. In this regard, the peritoneal cavity may be flooded with a cargo or drug of choice in an appropriate buffer. The source and counter electrodes
25 **200**, **500** may be positioned proximate to the target site of the pancreas, such as, for example, in a pancreatic duct and at an appropriate location or locations at the exterior of the pancreas near the tumor. Various arrangements of the source and counter electrodes may be implemented so that the cargo is positioned to interact with the electric field, upon actuation thereof, to drive the cargo to the target site of the pancreas. That is
30 one, both, or neither of the electrodes may be positioned substantially within the pancreas. For example, both electrodes may be positioned exterior to the pancreas and on opposite sides thereof. In one particular example, one of the electrodes may be arranged as a wire mesh arrangement that can be positioned on and contact an exterior surface of the pancreas. A current may then be applied to drive the cargo (e.g., drug or
35 therapeutic agent) from the peritoneal cavity to the pancreas and the site of the tumor. In another instance, the reservoir may be implanted in the intraperitoneal cavity such that

the reservoir is provided remotely from the source electrode **200** and the counter electrode **500**.

However, embodiments of the present invention may also be used in association with other cavities of the body, wherein at least some of these cavities are internal body cavities, while others are not. For example, the cargo may be delivered to the cranial cavity (brain cancers), the oral cavity (head and neck cancers, thyroid cancers), the thoracic cavity or mediastinum (thymus cancer, esophageal cancers and heart disease), the pleural cavity (lung cancers, cystic fibrosis, pulmonary fibrosis, emphysema, adult respiratory distress syndrome (ARDS), and sarcoidosis), the abdominopelvic cavity or peritoneal cavity (pancreatic cancer, liver cancers and metastases, stomach cancer, small bowel cancer, genital warts, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), renal cancers and metastases, splenic cancers, and Hodgkin's disease), and the pelvic cavity (testicular cancer, prostate cancer, ovarian cancer fallopian tube, cervical cancer, endometrial cancer, uterine cancers, Kaposi's sarcoma, colorectal cancers, and urinary bladder cancer).

In order to apply a voltage potential across the source electrode **200** and the counter electrode **500**, the source electrode **200** and the counter electrode **500** are in electrical communication. In this regard, the source electrode **200** and the counter electrode **500** are connected to a power source (not shown). In some instances, the power source may comprise a programmable power supply and function generator capable of generating both direct current and pulsed waveforms at various voltages and for various time intervals. The power source can generate the potential difference between the source electrode **200** and the counter electrode **500** necessary to induce electromigration and electroosmosis of the cargo (e.g., the therapeutic agent). A function generator allows for manipulation of the wave generated from the power source. Square, triangular, sawtooth, multi-step wave forms may be used to drive a direct current through the source and counter electrodes **200**, **500**.

As described above, the disclosed iontophoretic techniques may take either an inside-out or an outside-in approach in driving the cargo toward the target site of tissue. That is, reverse iontophoretic techniques may be employed in all of the embodiments described hereinabove, and as described, for example, in Example 8. In this regard, the source electrode may be disposed exterior to a duct, organ, tissue, or target site, while the counter electrode is positioned within a duct, lumen, organ, etc. such that the cargo is driven from outside the target site inwardly toward the target site.

Many modifications and other embodiments of the invention will come to mind to one skilled in the art to which this invention pertains having the benefit of the teachings presented in the foregoing description; and it will be apparent to those skilled in the art

that variations and modifications of the present invention can be made without departing from the scope or spirit of the invention. Therefore, it is to be understood that the invention is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended
5 claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

The following examples are presented by way of illustration, not by way of limitation.

EXPERIMENTAL

10 Example 1: Delivery of Rhodamine 6G Dye into Agarose Phantoms

A cylindrical tube of 2% (w/v) agarose gel in deionized (D.I.) water was fabricated as a phantom with an outer diameter (o.d.) = 2.5 cm and length ~ 3-4 cm. A concentric reservoir for holding the dye (o.d = 0.8 cm, length ~ 2 cm) was cored out from the top surface along the longitudinal axis of the gel cylinder. Electrodes were fabricated out of
15 aluminum foil (width ~ 0.5 cm, length ~ 15 cm, thickness ~ 0.1 cm). A solution of 0.5% Rhodamine 6G in D.I. water was used to model the delivery of a small molecule drug. The dye was filled inside the cored reservoir in the agarose phantom and the source electrode (anode, in this case) was inserted into the dye reservoir. The other end of the anode was hooked to a DC power source with an alligator clip. The agarose phantom
20 was immersed in a beaker containing 0.25x PBS solution, as shown in FIG. 17A. The cathode, a second piece of aluminum foil, was placed in the PBS beside the agarose phantom and hooked up to the DC power source. In the negative control, passive diffusion of the dye was allowed without any passage of current for 10 minutes. In the experimental condition, a constant current of 5 mA (voltage ~ 9.5V) was driven through
25 the electrodes for the same duration (10 minutes). As shown in FIG. 17B, to characterize the extent of iontophoretic transport, cross-sections of the agarose phantom were taken every 0.5 cm along the length. The radial transport of the dye from the edge of the cored reservoir was quantified. In the negative control (0 mA) dye was localized to the inner wall of the reservoir, while in the experimental condition (5 mA) the dye spread radially to
30 the edge of the agarose phantom.

Example 2: Unshielded Electrode Configurations for Control over Targeted Delivery to Specific *in vivo* Locations

Unshielded electrode configurations were developed for demonstrating control
35 over delivery to specific *in vivo* locations. These include electrodes fabricated out of metal wire (silver, silver chloride), metal foil (silver, platinum, aluminum) and wire mesh (aluminum), as shown in FIGS. 18A and 18B. These are representative examples, and

similar designs can be fabricated with variations in size, material and additional enhancements or refinements to the basic configuration. The advantages of wire and foil electrodes shown FIG. 18A are: simplicity and ease of use, flexibility for insertion into tiny orifices and ducts, precise control over size and potential for miniaturization. Their primary limitation is their tendency for hydrolysis of the conducting fluid medium. Silver electrodes are also susceptible to oxidation, while silver chloride electrodes can get reduced to metallic. As shown in FIG. 18B, wire mesh electrodes can be fabricated either in a stent configuration for intra-luminal placement, or as a patch or net configuration for placement on the outside surface of an organ or target tissue. Such a configuration may provide greater control over the surface area of delivery, as well as better heat flow to reduce the potential for tissue burns. Additionally, these may be fabricated from conducting polymers or coated with biodegradable polymers to create designs that are highly conformable to organ surface characteristics and geometrical contours.

15 Example 3: Insulated Electrode Configurations for Control over Targeted Delivery to Specific *in vivo* Locations

An insulated electrode was developed to demonstrate control over targeted delivery to specific *in vivo* locations. By insulating a portion of the electrode surface, it is possible to control the delivery to the tissue or organ systems in a well defined fashion. For example, the flux of drug or particles will be attenuated corresponding to the insulated areas of the electrode. Aluminum foil was folded into a long rectangular shape of appropriate dimensions (length ~ 10 cm, width ~ 0.4 cm, thickness ~ 0.1 cm). Insulating tape (width ~ 1 cm) was wrapped around the foil in alternating sections. This insulated electrode was immersed in the central reservoir of an agarose phantom (2% agarose w/v in deionized water), as shown in FIG. 19A. A solution of 0.5% Rhodamine 6G in D.I. water was used to model the delivery of a small molecule drug. The dye was filled inside the cored reservoir in the agarose phantom and the insulated source electrode (anode, in this case) was inserted into the dye reservoir. The agarose phantom was immersed in a beaker containing 0.25x PBS solution. A bare aluminum foil electrode served as a cathode, and was placed in the PBS beside the phantom. Both electrodes were hooked to a DC power source with alligator clips. In the negative control, passive diffusion of the dye was allowed without any passage of current for 10 minutes. In the experimental condition, a constant current of 5 mA (voltage ~ 9.5V) was driven through the electrodes for the same duration (10 minutes). To characterize the extent of iontophoretic transport, the agarose phantom was sectioned longitudinally. A difference is seen in the extent of transport from the sections of the phantom exposed to the unshielded sections of the

electrode, as compared to diffusion from the passive control, as shown in FIGS. **19B** and **19C**, respectively.

Example 4: Electrode Configurations with Built-in Drug Reservoirs

Since it may not be possible to confine the drug to be delivered within a localized cavity or lumen in the target tissue, electrodes with built-in drug reservoirs were developed. Such examples were fabricated by encapsulating insulated foil electrodes described earlier within an agarose gel matrix. The agarose gel containing the 0.5% Rhodamine 6G solution, serving as a model drug, was first poured into a glass test-tube of diameter 1.2 cm. The insulated electrode was then inserted into the gel solution. The gel was allowed to solidify, and the electrode was extracted by breaking the test tube. An agarose gel phantom with a central reservoir of inner diameter ~ 1.5 cm was prepared. This electrode was then inserted into the phantom and tested for iontophoretic delivery at a constant current of 5 mA for 10 minutes. The results show zones of controlled delivery through the gel that are visible under short wave UV light, as shown in FIG. **20B**. FIG. **20A** shows the electrode having the built-in drug reservoir being at least partially depleted of the model drug after completion of the experiment. Similar results were also seen in transport through muscle and fat tissue.

Example 5: Delivery of Dye into Muscle Tissue (Chicken Breast)

A soft-gel electrode was fabricated from 2% (w/v) agarose gel containing 5% Rhodamine 6G solution in D.I. water by casting the gel in a test tube (o.d. = 13 mm and length ~ 25 mm) with an aluminum foil electrode inserted along the central axis. Chicken breast was chosen as a representative tissue to demonstrate iontophoretic delivery in accordance with one embodiment of the present delivery system. A cylindrical core was removed from the center of the tissue sample to produce a drug reservoir of o.d. = 15 mm. The soft-gel electrode was then placed in the reservoir inside the tissue sample and the source electrode (anode, in this case) was hooked to a DC power source with an alligator clip. The tissue sample was immersed in a beaker containing deionized water. The cathode, a regular aluminum foil electrode without gel, was placed in the PBS beside the tissue sample and hooked up to the DC power source. In the negative control, passive diffusion of the dye into the tissue was allowed without any passage of current for 30 minutes. In the experimental condition, a constant current of 10 mA (voltage ~ 1.4 V) was driven through the electrodes for the same duration (30 minutes). To characterize the extent of iontophoretic transport, cross-sections of the tissue sample were taken every 0.5 cm along the depth of the sample, as shown in FIG. **21**. The radial transport of the dye from the edge of the drug reservoir was quantified. As shown in the top row of

FIG. 21, in the negative control (0 mA), the dye was localized to the inner wall of the reservoir. As shown in the bottom row of FIG. 21, in the experimental condition (10 mA), the dye spread in a radial direction into the tissue to a distance of ~ 5 mm from the edge of the reservoir.

5

Example 6: Delivery of Dye into Adipose Tissue (Bovine)

Bovine fat was chosen as another representative tissue to demonstrate iontophoretic delivery. A cylindrical core was removed from the center of the tissue sample to produce a drug reservoir of o.d. = 15 mm. A soft-gel electrode similar to the one described earlier, but with platinum foil (0.5 mm thick) as the source electrode, was then placed in the reservoir at the center of the tissue sample and was hooked to a DC power source with an alligator clip. The tissue sample was immersed in a beaker containing deionized water (mimicking filling the peritoneal cavity). A silver chloride electrode directly inserted into the tissue sample served as the cathode and was hooked up to the DC power source. In the negative control, passive diffusion of the dye into the fat tissue was allowed without any passage of current for 30 minutes. In the experimental condition, a constant voltage of 20 V was applied between the electrodes for the same duration (30 minutes). The current was allowed to increase from 5-15 mA to maintain constant potential difference. To characterize the extent of iontophoretic diffusion, cross-sections of the tissue sample were taken every 0.5 cm along the depth of the sample. The radial diffusion of the dye from the edge of the drug reservoir was quantified. In the negative control (0 V) dye was localized to the inner wall of the reservoir (not shown). In the experimental condition (20 V), a maximum penetration depth of ~ 8 mm from the edge of the reservoir was achieved, as shown in FIG. 22.

25

Example 7: Placement of Counter Electrodes for Control over Targeted Delivery to Specific *in vivo* Locations

As described previously, the position of the counter electrode may be manipulated to exert control over targeted delivery to specific *in vivo* locations. In this example, two possible configurations are illustrated in FIGS. 23A and 23B, which correspond to the configuration of FIGS. 13A and 13B, respectively. In the first configuration, the counter electrode was placed in direct point contact with the outside surface of the agarose gel phantom. In the second configuration, the counter electrode was wrapped around the mid-section of the gel, as shown in FIG. 23B. The agarose phantoms were the same as those used in Example 1, and a constant current of 5 mA was allowed to flow through the electrodes for 10 minutes. In the first configuration, highly directional diffusion was seen on the side of the agarose phantom with direct counter electrode contact, as shown in

30

35

FIG. **23A**. In the second configuration, a broader diffusion band is seen around the midsection, demonstrating greater diffusivity towards the counter electrode wrapped around the phantom.

5 Example 8: Delivery of Dye Using Reverse Iontophoresis

The ability to extract a small molecule from the surrounding medium (like filling the peritoneal cavity) into a reservoir located inside an agarose phantom was demonstrated by employing the principle of reverse iontophoresis. To allow diffusion from the outside surface of the gel to the central reservoir, the phantom was placed in a solution of
10 Rhodamine 6G in deionized water. For this application, the polarity of the electrodes was switched, with the counter electrode being placed in the central drug reservoir, while the source electrode was placed in the dye solution outside the gel, as shown in FIG. **24A**. The electrodes were then hooked to a DC power source with an alligator clip. In the negative control, the gel was soaked in the dye solution without any passage of current
15 for 10 minutes. In the experimental condition, a constant current of 5 mA (voltage ~ 9.5V) was driven through the electrodes for the same duration (10 minutes). To characterize the extent of reverse iontophoretic diffusion, cross-sections of the agarose phantom were taken every 0.5 cm along the length. The radial diffusion of the dye from the outside surface of the gel to the inside edge of the central reservoir was quantified. In the
20 negative control (0 mA) dye was localized to the outer wall of the gel, as shown in the top row of FIG. **24B**. In the experimental condition (5 mA) the dye spread radially toward the central reservoir and collected there, as shown in the bottom row of FIG. **24B**. In the experimental condition, the total volume of dye accumulated in 10 minutes was sufficient to fill up a 3 mL glass vial, as shown in the bottom vial of FIG. **24B**. This example
25 demonstrates the potential of the invention for delivering drug molecules from the outside surface of an organ to the inner core. It also demonstrates an application requiring the extraction of a toxin from the target tissue into a central reservoir from which it can be safely and easily extracted.

30 Example 9: Variable Delivery of Rhodamine 6G Dye into Agarose Phantoms using Independently Controlled Electrodes

An assembly of two independently-powered, insulated electrodes was developed to demonstrate variable controlled delivery, as described previously. By allowing independent control over parameters for iontophoretic delivery such as current, voltage
35 and time, we were able to demonstrate variable delivery zones at two distinct sites within the same lumen. Two insulated aluminum foil electrodes similar to the one shown in Example 3 above, were combined into a single assembly according to the schematic

shown in FIG. 5. The insulated double-electrode assembly was immersed in the central reservoir of an agarose phantom (2% agarose w/v in deionized water). A solution of 0.5% Rhodamine 6G in D.I. water was used to model the delivery of a small molecule drug and was filled inside the cored reservoir in the agarose phantom. The agarose

phantom was immersed in a beaker containing 0.25x PBS solution. A pair of bare aluminum foil electrodes served as cathodes, and were placed in the PBS beside the phantom. Both sets of electrodes were hooked to two independent DC power sources with alligator clips. In the negative control, passive diffusion of the dye was allowed without any passage of current for 5 minutes. In the experimental condition, one

electrode was set for a constant current of 5mA, while the other was operated at a constant voltage of 20 V. Duration of delivery was held constant at 5 minutes, but as noted earlier, all of the above parameters can be independently controlled. To

characterize the extent of iontophoretic diffusion, the agarose phantom was sectioned longitudinally. Under UV light, a difference is seen in the extent of diffusion from the

sections of the phantom exposed to the uninsulated sections of both electrodes in the assembly, as shown in FIG. 25. For example, the bottom electrode shows uniform diffusion at the bottom of the well, whereas the uninsulated section of the top electrode shows more diffusion on the bare (anterior) side as opposed to the insulated (posterior) side. This example demonstrates that a similar electrode assembly can be used to

control the location and extent of delivery at multiple proximal sites within the same lumen or its branches. This may be particularly useful in targeted delivery to metastatic tumors within the same organ that can be accessed through a common ductal or vascular network.

Example 10: Variable Delivery of Rhodamine 6G Dye into Agarose Phantoms using Independently Controlled Electrodes with Built-in Drug Reservoir

A variation of the double-electrode assembly previously described in Example 9 was developed with a built-in drug reservoir. The insulated double-electrode assembly was immersed in a test-tube of 2% agarose gel containing a 5 mg aqueous solution of Rhodamine 6G. The soft-gel electrode assembly was then inserted into an 2% agarose phantom having a cored out central cavity (diameter: 1.5 mm). The agarose phantom was immersed in a beaker containing 0.25x PBS solution, as shown in FIG. 26A. Two bare aluminum foil electrodes served as cathodes, and were placed in the PBS beside the phantom. Both sets of electrodes were hooked to two independent DC power sources with alligator clips. In the negative control, passive diffusion of the dye was allowed without any passage of current for 7 minutes. To demonstrate independent control of both electrodes, one electrode was set for a constant current of 5 mA for 5 minutes, while

the other was operated at a constant current of 15 mA for 7 minutes. To characterize the extent of iontophoretic diffusion, the agarose phantom was sectioned longitudinally. Under UV light, a difference is seen in the extent of diffusion from the sections of the phantom exposed to the uninsulated sections of both electrodes in the assembly, as shown in FIG. 26B. Depletion of the dye is seen from the areas of the gel exposed to uninsulated tips of the electrodes. Furthermore, two distinct delivery zones can be seen resulting from the two independently controlled electrodes.

Example 11: Delivery of Doxorubicin into Agarose Phantoms

A cylindrical tube of 2% (w/v) agarose gel in deionized (D.I.) water was fabricated as a phantom with an outer diameter (o.d.) = 2.5 cm and length ~ 3-4 cm. A concentric reservoir for holding the dye (o.d. = 0.8 cm, length ~ 2 cm) was cored out from the top surface along the longitudinal axis of the gel cylinder. Electrodes were fabricated out of platinum foil (width ~ 0.25 cm, length ~ 3 cm, thickness ~ 0.05 cm). A solution of .25% Doxorubicin in 4.875% DMSO and 94.875% DI water was used to model the delivery of a small molecule drug. The dye was filled inside the cored reservoir in the agarose phantom and the source electrode (anode, in this case) was inserted into the dye reservoir. The other end of the anode was hooked to a DC power source with an alligator clip. The agarose phantom was immersed in a beaker containing DI water. The cathode, a second piece of platinum foil, was placed in the PBS beside the agarose phantom and hooked up to the DC power source. In the negative control, passive diffusion of the dye was allowed without any passage of current for 5 minutes. In the experimental condition, a constant current of 5 mA (voltage ~ 9.5V) was driven through the electrodes for the same duration (5 minutes). As shown in FIG. 27, to characterize the extent of iontophoretic diffusion, cross-sections of the agarose phantom were taken every 0.5 cm along the length. The radial diffusion of the dye from the edge of the cored reservoir was quantified. In the negative control (0 mA) dye was localized to the inner wall of the reservoir (bottom row), while in the experimental condition (5 mA) the dye spread radially to the edge of the agarose phantom (top row).

Example 12: Injection of Rhodamine 6G into Pancreatic Duct and Placement of Electrodes on Outer Surface of Pancreas

As shown in FIG. 28A, Liquified 2% (w/v) agarose gel containing 0.5% Rhodamine 6G solution in D.I. water was injected into the pancreas duct through a 18G IV catheter, where it solidified upon contact. The source electrode, made of aluminum foil, was placed on one side of the pancreas, and the counter electrode, made of aluminum foil, was placed on the opposite side of the pancreas. The electrodes were

hooked to a DC power source with alligator clips. The tissue sample was immersed in a beaker of DI water. In the experimental condition, a constant current of 5 mA (voltage ~ 2.4 V) was driven through the electrodes for the same duration (30 minutes). To characterize the extent of iontophoretic diffusion, cross-sections of the tissue sample were taken every 0.5 cm along the depth of the sample, as shown in FIG. **28B**. The radial diffusion of the dye from the edge of the drug reservoir was quantified. In the experimental condition (5 mA), the dye spread in a radial direction into the tissue to a distance of ~ 3 mm from the edge of the reservoir.

10 Example 13: Delivery of Dye into Pancreas using Flat Electrodes

A soft-gel source electrode was fabricated from Liquified 2% (w/v) agarose gel containing 0.5% Rhodamine 6G solution in D.I. water by casting the gel in a Petri dish with an aluminum foil electrode inserted on top of gel. The source electrode was placed on one side of the pancreas, and the counter electrode was placed on the opposite side of the pancreas. The electrodes were hooked to a DC power source with alligator clips. The tissue sample was immersed in a beaker of DI water. In the experimental condition, a constant current of 5 mA (voltage ~ 2.4 V) was driven through the electrodes for the same duration (30 minutes). As shown in FIG. **29**, in the experimental condition (5 mA), the dye moved from the agarose source electrode into the tissue.

20 Example 14: Delivery of Dye through Pancreatic Duct using Probe Electrode

A soft-gel source electrode was fabricated from Liquified 2% (w/v) agarose gel containing 0.5% Rhodamine 6G solution in D.I. water by casting the gel in a test tube (o.d. = 5 mm and length ~25 mm) with platinum wire inserted along the central axis. The soft-gel source electrode was probed into the pancreatic duct, and the counter electrode, made of platinum foil, was placed on the outer surface of the pancreas, as shown in FIG. **30A**. The electrodes were hooked to a DC power source with alligator clips. The tissue sample was immersed in a beaker of DI water. In the negative control, passive diffusion of the dye into the tissue was allowed without any passage of current for 30 minutes. In the experimental condition, a constant current of 20 mA (voltage ~ 9.2 V) was driven through the electrodes for 30 minutes. To characterize the extent of iontophoretic diffusion, cross-sections of the tissue sample was taken every 1 cm along the depth of the sample. As shown in FIG. **30B**, in the experimental condition (20 mA), the dye moved from the agarose source electrode into the tissue. As shown in FIG. **30C**, in the negative control (0 mA), the dye was localized to the inner wall of the pancreatic duct. In the experimental condition (20 mA), the dye spread in a radial direction into the tissue to a distance of ~3 mm from the edge of the reservoir.

Example 15: Delivery of PRINT[®] Nanoparticles into Agarose Phantoms

A miniaturized agarose phantom was used to demonstrate the delivery of PRINT[®] nanoparticles using iontophoresis. A 2% agarose gel was poured into a small test tube (diameter 13 mm) and a capillary tube (o.d. 1 mm) was used to create a central reservoir. An aqueous solution of fluorescent polyampholyte PRINT[®] nanoparticles (size: 343 nm, charge: ~ 59 mV, concentration: 9.5 mg/mL) was deposited into the reservoir. A platinum wire (diameter 0.25 mm) was inserted into the reservoir as anode and a similar wire served as a cathode outside the phantom. The phantom was then immersed in a solution of 0.25x PBS, and the electrodes were hooked up to a DC power source using alligator clips. In the negative control, the particles were allowed to passively diffuse into the gel without the application of current for 5 minutes. For iontophoretic delivery, the nanoparticles were driven into the gel by a constant current of 5 mA for the same duration. The phantoms were then cut into 1 mm thick transverse slices that were placed onto glass slides for imaging under a fluorescent microscope. The difference in the extent of migration due to the electric field is shown in FIGS. **31A** and **31B**. FIG. **31A** represents passive diffusion, while FIG. **31B** shows results from migration in the 5 mA current.

The following examples, which are not meant to be limiting, generally relate to proof-of-concept studies relating to electric field assisted delivery (EFAD), engineering of EFAD devices, exploratory studies in large animals have been performed, and methods of pharmacokinetic analysis for local delivery mechanisms have been developed. Proof-of-concept studies for EFAD were performed in tumor tissue surrogates and pancreatic tumor tissue. Two EFAD devices were designed and prototyped for different approaches to the primary pancreatic tumor, including endoductal, and surgically implantable. Four large animal models were evaluated for the different device approaches, and the canine model was chosen as the most amenable to all device approaches. A tissue sampling system and methods of pharmacokinetic analysis for tissue and plasma have also been developed. Overall, these devices could potentially offer an entirely new modality for the treatment of pancreatic cancer under the emerging field of interventional oncology. Moreover, the further development of these devices could translate directly into new treatments for other types of primary tumors and metastatic diseases.

Example 16: Examination of Gemcitabine Transport in Pancreatic Tissue and Tumor Tissue

To assess and optimize the electrical transport parameters in tissue, a transport testing system was built (see FIG. 32A). The transport of gemcitabine, the current

standard-of-care therapy for pancreatic cancer, was evaluated in orthotopic xenograft tumors using this transport testing system (see FIG. 32B). The tumors chosen for the studies were 1.25 to 1.5 cm in diameter because of compatibility with the size of the transport cell. The gemcitabine was used according to the current clinical formulation (Gemzar® to Eli Lilly and Company), at a concentration relevant to that administered in the clinic. For three tumors, a constant current of 20mA was applied for 20 minutes, and the amount of gemcitabine was evaluated using a high-performance liquid chromatography (HPLC) analysis method. For three additional tumors, no current was applied, which allowed for passive diffusion of the gemcitabine into the tumor, and the amount of gemcitabine was evaluated using the same HPLC analysis method. As shown in FIG. 32B, an eight-fold increase in the amount of gemcitabine was measured within an orthotopic xenograft tumor when a constant current of 20mA was applied for 20 minutes compared to the control (no current applied).

15 Example 17: Implantable Device

The laparoscopic implantable device was developed for surgical implantation onto the surface of the pancreas in proximity to the tumor. The device would be sutured or bioadhered to the pancreas. As seen in FIGS. 33A-D, the laparoscopic implantable system was designed with a drug reservoir, cellulose membrane, polyurethane shell, AgCl electrode, conducting wire, and an inlet and outlet for drug flow into and out of the reservoir. The reservoir is covered by a semi-permeable membrane through which drug can be transported. Drug flows through an inlet tube and is removed from the reservoir through an outlet tube. A metallic electrode is situated at the back of the reservoir. A conducting wire is situated through the reservoir to connect to the metallic electrode. There exist anchor points on the device situated for attachment to tissue. The reservoir and flow system allow for a constant drug concentration around the electrode and the removal of the by-products of the redox reaction. The cellulose membrane will minimize uncontrolled drug flow out of the system.

30 Example 18: Studies in Large Animals

As there are no readily available large animal models of pancreatic cancer, device development and evaluation will be performed in healthy large animals. Four large animal models, including goats, sheep, dogs, and pigs, were evaluated for three device approaches to the pancreas. Table 1 shows the relative assessment of each animal model. The dog was determined to be the most amenable to all device approaches.

Animal	Surgical	Endoscopic	Intravascular
Goat	2	2	5
Sheep	2	2	5
Dog	4	4	4
Pig	2	2	4

Table 1: Assessment of animal model for device approach.
Scale: (1) Not feasible – (5) Very feasible

The reservoir based system similar to that shown in FIGS. 33A-D was surgically implanted onto the pancreas of a canine. All animal models were anesthetized and attached to a respirator for the entirety of the study. The implantable device approach was assessed via a laparotomy. The pancreas was assessed for ease of access.

There were three arms for the large animal experiment: 1. Device with current; 2. Device without current; and 3. IV Infusion (see Table 2). The device was sutured onto the right lobe of the canine pancreas. Gemcitabine formulated at clinically relevant concentrations was pumped into and out of the device at ~1.5 mL/min during the application of 10mA of current applied for 60 minutes. Control experiments were run without current. After administration of therapy, the pancreas was excised and snap frozen for analysis. The gemcitabine was measured from the section tissue using UV-HPLC from established protocols in the literature (see Olive, KP, *et al.* Science 324 (2009) 1457-1461 and Kirstein MN, *et al.*, J Chromatogr B Analyt Technol Biomed Life Sci. 835 (2006) 136-142). Shown in FIG. 34 are the results obtained from the three experimental arms analyzing the mass of gemcitabine from the entire pancreas.

	Device w/Current	Device w/o Current	IV Infusion
Current	10 mA	0 mA	-
Time of Administration	60 minutes	60 minutes	30 minutes
Sample Size	5	5	4

Table 2: Experimental arm parameters

In FIG. 35, the transport distance of the gemcitabine is shown for the with and without current arms. In particular, FIG. 35 shows the quantification of gemcitabine mass at different distances away from the electrode. The plasma concentrations determined for the with and without current arms are given in Table 3. Plasma concentrations of gemcitabine were detected at 15-minute increments prior to and during the large animal study. The tissue was sectioned using a cryostat microtome and gemcitabine was

extracted using an established extraction method (see Olive *et al.*). The gemcitabine was detected and quantified using UV-HPLC (see Olive *et al.* and Kirstein *et al.*). Essentially, the gemcitabine levels detected in the plasma of the dogs was below the detectable limit.

	Device - Current Applied	Device - No Current
Sample	Gem Concentration (ug/mL)	Gem Concentration (ug/mL)
-15 min	*	*
0 min	*	*
15 min	*	*
30 min	*	*
45 min	*	*
60 min	*	*

Table 3: Plasma Concentrations of Gemcitabine. *- Below limit of detection

5

Pharmacokinetics and Analysis in Tissue and Serum

The pharmacokinetic analysis for tissue and serum has been developed according to a method developed by Kirstein *et al.* A validated standard curve has been developed and will be used for future *in vivo* studies (data not shown).

10

Example 19: Endoductal device

A second device approach developed for the treatment of pancreatic cancer was an endoductal device. The device was modeled in a 3D CAD program (SolidWorks® to Dassault Systèmes SolidWorks Corporation) prior to prototyping. The endoductal approach was developed according to endoscopic retrograde cholangiopancreatography (ERCP) devices, which use a duodenoscope to access the major duodenal papilla. A double balloon catheter was designed, as seen in FIG. 36. A multi-luminal tube was used for independent control of balloons, drug expulsion, and electrical contact with the electrode. The catheter contains two independently controlled balloons that sandwich an electrode. The balloons and electrode are UV-cured to the tube. A guide wire is attached to the front end of the device. Drug can be expelled from the device around the electrode and would fill the cavity between the two independently controlled balloons. A conducting wire is in contact with the silver electrode.

The tubing of the catheter contained four lumens for saline, drug, and a conducting wire (see FIG. 37). The two identical lumens were used to inflate the balloons with saline, the small lumens were used for the conducting wire, and the larger lumen was used for the transport of drug. FIG. 37 illustrates exemplary dimensions for the catheter and lumens according to one experimental implementation and is not meant to be limiting. A nitinol conducting wire was connected to a silver electrode located between two pre-fashioned urethane balloons. The double balloon catheter system created a reservoir for drug containment, which could limit drug exposure to the epithelium; allow

for good electrical contact between the electrode and drug, and reduce the effect of extraneous ions in the system. Ultimately, an endoductal EFAD device could be designed to slip over a guide wire that has entered the main pancreatic duct.

WHAT IS CLAIMED IS:

1. A delivery system for local drug delivery to a target site of internal body tissue, comprising:

a source electrode adapted to be positioned proximate to a target site of internal body tissue;

5 a counter electrode in electrical communication with the source electrode, the counter electrode being configured to cooperate with the source electrode to form a localized electric field proximate to the target site; and

a reservoir capable of interacting with the localized electric field, the reservoir being configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field formed between the source electrode and the counter electrode.

2. A delivery system according to Claim 1, further comprising an electrode deployment device configured to insert at least one of the source electrode and the counter electrode proximate to the target site of internal body tissue *in vivo*.

3. A delivery system according to Claim 2 further comprising a control system in communication with the electrode deployment device, the control system being configured to guide the electrode deployment device with placement of the source electrode and the counter electrode.

4. A delivery system according to Claim 2 wherein the electrode deployment device comprises one of a catheter device, an endoscopic device, a laparoscopic device, an implantable device, and combinations thereof.

5. A delivery system according to Claim 4 wherein the catheter device comprises a first and second expandable member serially disposed along a longitudinal axis of the catheter device, the source electrode being axially disposed between the first and second expandable members such that, upon inflation of the first and second expandable members to occlude the target site, the target site is isolated and the delivery of the cargo is contained to the target site.

6. A delivery system according to Claim 4 wherein the catheter device comprises a perforated polymer sheath, the cargo being capable of exiting the catheter device through a plurality of perforations defined by the perforated polymer sheath, and

the source electrode comprising an array of probes terminating at different lengths and being independently powered such that the probes are capable of being variably controlled, the source electrode further comprising a plurality of insulating members disposed about and between the probes so as to form cargo delivery zones substantially aligned with the perforations of the perforated polymer sheath.

7. A delivery system according to Claim 4 wherein the endoscopic device comprises a proximal end and a distal end having the source electrode disposed thereabout for positioning proximate to the target site, the source electrode comprising a hollow needle member forming the reservoir, the proximal end having a port to fluidly connect the proximal and distal ends such that the reservoir is capable of being remotely filled with the cargo.

8. A delivery system according to Claim 1 wherein the cargo comprises at least one of small ionic molecules, nucleic acids, proteins, organic nanoparticles, therapeutic agents, and imaging agents.

9. A delivery system according to Claim 1 wherein the source electrode includes an array of probes comprising one of thin wires, foil, mesh, pellets, disks, stents, clamps, prongs, clips, needles, hollow tubes, and combinations thereof.

10. A delivery system according to Claim 1 wherein the source electrode and the counter electrode are comprised of one of a metallic material, a conductive polymer material, and combinations thereof.

11. A delivery system according to Claim 1 further comprising at least one insulating member at least partially disposed about the source electrode, the at least one insulating member being configured to confer directionality to the transport profile of the cargo released from the reservoir.

12. A delivery system according to Claim 1 wherein the source electrode comprises an array of probes, at least one of the probes comprising an imaging device such that the source electrode is capable of being imaged for positioning thereof proximate to the target site.

13. A delivery system according to Claim 1 wherein the counter electrode includes an ion selective membrane disposed at least partially thereabout for limiting interference of non-cargo ions with the cargo to be delivered to the target site.

5 14. A delivery system according to Claim 1 further comprising a coolant device operably engaged with the counter electrode, the coolant device being configured to provide cooling to the counter electrode during use thereof to form the electric field.

10 15. A delivery system according to Claim 1 wherein the reservoir is comprised of a polymer matrix at least partially encapsulating the source electrode, the polymer matrix incorporating the cargo therein such that upon activation of the electric field the cargo diffuses out of the polymer matrix and toward the counter electrode.

15 16. A delivery system according to Claim 15 wherein the source electrode includes at least one insulating member at least partially disposed thereabout such that the polymer matrix further encapsulates the at least one insulating member, the at least one insulating member being configured to confer directionality to the transport profile of the cargo released from the reservoir.

20 17. A delivery system according to Claim 15 wherein the source electrode comprises an array of probes terminating at different lengths and being independently powered such that the probes are capable of being variably controlled, the source electrode further comprising a plurality of insulating members disposed about and between the probes so as to form cargo delivery zones.

25 18. A delivery system according to Claim 1 wherein a polymer matrix at least partially encapsulates the counter electrode, the polymer matrix being configured to receive and retain a target substance so as to extract the target substance from the target site.

30 19. A delivery system according to Claim 1 wherein the counter electrode is configured to contact the target site so as to promote directional transport of the cargo toward the target site.

35 20. A delivery system according to Claim 1 wherein the reservoir is remotely disposed from the source electrode, the reservoir and the source electrode being in fluid

communication via a hollow conduit member to facilitate transfer of the cargo from the reservoir proximate to the source electrode.

21. A delivery system according to Claim 1 wherein the reservoir and source electrode are operably engaged so as to form a single assembly.

22. A delivery system according to Claim 1 wherein the reservoir comprises a patch member impregnated with the cargo, the patch member being adapted for implantation proximate to the target site.

23. A delivery system according to Claim 1 wherein the counter electrode comprises a patch member configured to be applied externally to a body member such that the source electrode and the counter electrode are positioned on opposing sides of the target site or near the target site to which the cargo is to be delivered.

24. A delivery system according to Claim 1 wherein the source electrode and the counter electrode each comprises a patch member, the patch member of the source electrode having the cargo incorporated therein.

25. A delivery system according to Claim 24 wherein the source and counter electrode patch members are disposed on the surface of the target site of a body organ.

26. A method of delivering a cargo to a target site of internal body tissue, the method comprising:

disposing a source electrode proximate to a target site of internal body tissue *in vivo*;

disposing a counter electrode in electrical communication with the source electrode, the counter electrode being configured to cooperate with the source electrode to form a localized electric field proximate to the target site;

disposing a reservoir such that the reservoir is capable of interacting with the localized electric field, the reservoir being configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field formed between the source electrode and the counter electrode; and

applying a voltage potential across the source and counter electrodes to form an electric field, thereby delivering at least a portion of the cargo to the target site.

5 27. A method according to Claim 26, wherein disposing the source electrode comprises disposing the source electrode proximate to the target site of internal body tissue *in vivo* using an electrode deployment device.

10 28. A method according to Claim 27 further comprising guiding the electrode deployment device with a control system in communication therewith, the control system being configured to guide the electrode deployment device for positioning of the source electrode and the counter electrode.

15 29. A method according to Claim 27 wherein disposing a source electrode further comprises disposing a source electrode with an electrode deployment device comprising one of a catheter device, an endoscopic device, a laparoscopic device, an implantable device, and combinations thereof.

20 30. A method according to Claim 29 wherein disposing a source electrode further comprises disposing a source electrode with an electrode deployment device comprising a catheter device having a first and second expandable member serially disposed along a longitudinal axis of the catheter device, the source electrode being axially disposed between the first and second expandable members such that, upon inflation of the first and second expandable members to occlude the target site, the target
25 site is isolated and the delivery of the cargo is contained to the target site.

 31. A method according to Claim 29 wherein disposing a source electrode further comprises disposing a source electrode with an electrode deployment device comprising a catheter device having a perforated polymer sheath, the cargo being
30 capable of exiting the catheter device through a plurality of perforations defined by the perforated polymer sheath, and the source electrode comprising an array of probes terminating at different lengths and being independently powered such that the probes are capable of being variably controlled, the source electrode further comprising a plurality of insulating members disposed about and between the probes so as to form
35 cargo delivery zones substantially aligned with the perforations of the perforated polymer sheath.

32. A method according to Claim 29 wherein disposing a source electrode further comprises disposing a source electrode with an electrode deployment device comprising an endoscopic device having a proximal end and a distal end having the source electrode disposed thereabout for positioning proximate to the target site, the source electrode comprising a hollow needle member forming the reservoir, the proximal end having a port to fluidly connect the proximal and distal ends such that the reservoir is capable of being remotely filled with the cargo.

33. A method according to Claim 26 wherein disposing a reservoir further comprises disposing a reservoir configured to carry a cargo comprising at least one of small ionic molecules, nucleic acids, proteins, organic nanoparticles, therapeutic agents, and imaging agents.

34. A method according to Claim 26 wherein disposing a source electrode further comprises disposing a source electrode having an array of probes comprising one of thin wires, foil, mesh, pellets, disks, stents, clamps, prongs, clips, needles, hollow tubes, and combinations thereof.

35. A method according to Claim 26 wherein disposing a source electrode and a counter electrode further comprises disposing a source electrode and a counter electrode comprised of one of a metallic material, a conductive polymer material, and combinations thereof.

36. A method according to Claim 26 further comprising disposing at least one insulating member at least partially about the source electrode, the at least one insulating member being configured to confer directionality to the transport profile of the cargo released from the reservoir.

37. A method according to Claim 26 wherein disposing a source electrode further comprises disposing a source electrode having an array of probes, at least one of the probes comprising an imaging device such that the source electrode is capable of being imaged for positioning thereof proximate to the target site.

38. A method according to Claim 26 wherein disposing a counter electrode further comprises disposing a counter electrode having an ion selective membrane disposed at least partially thereabout for limiting interference of non-cargo ions with the cargo to be delivered to the target site.

39. A method according to Claim 26 further comprising operably engaging a coolant device with the counter electrode, the coolant device being configured to provide cooling to the counter electrode during use thereof to form the electric field.

5

40. A method according to Claim 26 wherein disposing a reservoir further comprises encapsulating a reservoir comprised of a polymer matrix at least partially about the source electrode, the polymer matrix incorporating the cargo therein such that upon activation of the electric field the cargo diffuses out of the polymer matrix and toward the counter electrode.

10

41. A method according to Claim 40 wherein disposing a source electrode further comprises disposing a source electrode having at least one insulating member at least partially disposed thereabout such that the polymer matrix further encapsulates the at least one insulating member, the at least one insulating member being configured to confer directionality to the transport profile of the cargo released from the reservoir.

15

42. A method according to Claim 40 wherein disposing a source electrode further comprises disposing a source electrode having an array of probes terminating at different lengths and being independently powered such that the probes are capable of being variably controlled, the source electrode further comprising a plurality of insulating members disposed about and between the probes so as to form cargo delivery zones.

20

43. A method according to Claim 26 wherein disposing a counter electrode further comprises disposing a counter electrode having a polymer matrix at least partially encapsulating the counter electrode, the polymer matrix being configured to receive and retain a target substance so as to extract the target substance from the target site.

25

44. A method according to Claim 26 wherein disposing a counter electrode further comprises disposing a counter electrode such that the counter electrode contacts the target site so as to promote directional transport of the cargo toward the target site.

30

45. A method according to Claim 26 wherein disposing a reservoir further comprises disposing a reservoir remotely from the source electrode, the reservoir and the source electrode being in fluid communication via a hollow conduit member to facilitate transfer of the cargo from the reservoir proximate to the source electrode.

35

46. A method according to Claim 26 further comprising operably engaging the reservoir and the source electrode so as to form a single assembly.

5 47. A method according to Claim 26 wherein disposing a reservoir further comprises disposing a reservoir comprising a patch member carrying the cargo, the patch member being configured for implantation proximate to the target site.

10 48. A method according to Claim 26 wherein disposing a counter electrode further comprises disposing a counter electrode comprising a patch member configured to be applied externally to a body member such that the source electrode and the counter electrode are positioned on opposing sides of the target site or near the target site to which the cargo is to be delivered.

15 49. A method of treating a target site of body tissue, the method comprising: delivering a therapeutic agent to a body cavity of a patient for storage thereof; positioning a first electrode proximate to a target site of internal body tissue; positioning a second electrode such that the second electrode is in electrical communication with the first electrode; and
20 applying a voltage potential across the first and second electrodes to drive the therapeutic agent from the body cavity to the target site.

50. A method according to Claim 49 wherein delivering a therapeutic agent to a body cavity further comprises implanting a device within the body cavity, the device being configured to carry and release the therapeutic agent upon the voltage potential
25 being applied between the first and second electrodes.

51. A method according to Claim 49 wherein delivering a therapeutic agent to a body cavity further comprises delivering a therapeutic agent to one of a peritoneal cavity, a cranial cavity, an oral cavity, a pleural cavity, an abdominopelvic cavity, and a
30 pelvic cavity.

52. A method according to Claim 51 wherein positioning a first electrode further comprises positioning a first electrode in a pancreatic duct of the pancreas.

35 53. A method according to Claim 51 wherein positioning a second electrode further comprises positioning a second electrode having a wire mesh arrangement on an exterior surface of the pancreas.




FIG. 1A




FIG. 1B




FIG. 1C






FIG. 1D




FIG. 1E




FIG. 1F




FIG. 1G




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8B

FIG. 8A






FIG. 9






FIG. 12




FIG. 13B

FIG. 13A





FIG. 14






FIG. 16

22/43




FIG. 17B




FIG. 17A




FIG. 18B




FIG. 18A

24/43




FIG. 19A




FIG. 19B




FIG. 19C

25/43




FIG. 20B



FIG. 20A

26/43




FIG. 21

27/43




FIG. 22

28/43




FIG. 23B



FIG. 23A




FIG. 24B




FIG. 24A

30/43




FIG. 25

31/43




FIG. 26A




FIG. 26B

32/43




FIG. 27

33/43




FIG. 28B




FIG. 28A

34/43



FIG. 29

35/43



FIG. 30A



FIG. 30C



FIG. 30B

37/43




FIG. 31B



FIG. 31A




FIG. 32B





FIG. 32A



FIGS. 33A-D

40/43




FIG. 34




FIG. 35

42/43




FIG. 36




FIG. 37

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/025416

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61N1/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2005/171575 A1 (DEV NAGENDU B [US] ET AL) 4 August 2005 (2005-08-04) abstract; figures 1-3 paragraphs [0008] - [0011] paragraphs [0044] - [0054] paragraphs [0070] - [0073] -----	1-7
X	US 2002/151866 A1 (LUNDKVIST ANDRE-JEAN S [US] ET AL) 17 October 2002 (2002-10-17) abstract; figures 1A-3 paragraphs [0023] - [0024] paragraphs [0031] - [0040] ----- -/--	1-4,7

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 May 2010

Date of mailing of the international search report

20/07/2010

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Scheffler, Arnaud

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2010/025416

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/17837 A1 (IOTEK INC [US]) 15 April 1999 (1999-04-15) abstract; figures 7-9 page 2, line 25 - page 3, line 35 pages 5-7 pages 10-12 -----	1-6
X	WO 2007/111365 A1 (TRANSCUTANEOUS TECH INC [JP]; MITOBE RYO [JP]) 4 October 2007 (2007-10-04) abstract; figures 1-4 paragraphs [0016] - [0029] paragraphs [0055] - [0080] -----	1-5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2010/025416

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26-53
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 26-53

Claims 26-53 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 39.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims.

Claims 26-53 have not been searched, because they deal with methods of delivering a cargo to a target site (Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7

A delivery system for local drug delivery comprising an electrode deployment device

2. claims: 1, 2, 8, 15-17, 19, 21, 22

A delivery system for local drug delivery comprising a reservoir of polymer matrix

3. claims: 1, 9-12, 24, 25

A delivery system for local drug delivery comprising different source electrodes

4. claims: 1, 13, 14, 18, 20, 23

A delivery system for local drug delivery comprising different counter electrodes

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2010/025416

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2005171575	A1	04-08-2005	NONE	
US 2002151866	A1	17-10-2002	NONE	
WO 9917837	A1	15-04-1999	AU 9788098 A US 6139538 A	27-04-1999 31-10-2000
WO 2007111365	A1	04-10-2007	NONE	

专利名称(译)	介入给药系统和相关方法		
公开(公告)号	EP2401027A1	公开(公告)日	2012-01-04
申请号	EP2010707731	申请日	2010-02-25
[标]申请(专利权)人(译)	北卡罗来纳大学查珀尔希尔分校 流体科技公司		
申请(专利权)人(译)	教堂山北卡罗来纳大学 LIQUIDIA TECHNOLOGIES , INC.		
当前申请(专利权)人(译)	教堂山北卡罗来纳大学 LIQUIDIA TECHNOLOGIES , INC.		
[标]发明人	DESIMONE JOSEPH NAPIER MARY PILLAI JONATHAN BYRNE JAMES ROUSH LUKAS MILLER YEH JEN JEN PARROTT MATT		
发明人	DESIMONE, JOSEPH NAPIER, MARY PILLAI, JONATHAN BYRNE, JAMES ROUSH, LUKAS, MILLER YEH, JEN, JEN PARROTT, MATT		
IPC分类号	A61N1/30 A61B18/00 A61B18/14 A61N1/32		
CPC分类号	A61B18/1492 A61B2018/00214 A61B2018/00898 A61N1/306 A61N1/327 A61N1/0428 A61N1/325 A61K9/0002 A61K9/0009 A61K9/0024 A61L31/16 A61N1/00 A61N1/044 A61N1/0444 A61N1/0448 A61N1/05 A61N1/0507 A61N1/30 A61N1/303 A61N1/36002		
优先权	61/155880 2009-02-26 US		
其他公开文献	EP2401027B1		
外部链接	Espacenet		

摘要(译)

提供了用于向局部身体组织的目标部位递送局部药物的递送系统。递送系统包括源电极，其适于定位在靠近体内组织的目标部位。对电极与源电极电连通，并配置成与源电极配合以形成靠近靶位点的局部电场。储存器配置成使得储存器能够与局部电场相互作用。储存器配置成承载能够在暴露于局部电场时被输送到目标位置的货物。还提供了相关方法。

